Role of complement and NK cells in antibody mediated rejection

Human Immunology

Volumn 73, Issue 12, 2012, Pages 1226-1232

  Akiyoshi, Takurin ^a   Hirohashi, Tsutomu ^a   Alessandrini, Alessandro ^a   Chase, Catherine M ^a   Farkash, Evan A ^a   Neal Smith, R ^a   Madsen, Joren C ^a   Russell, Paul S ^a   Colvin, Robert B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD56 ANTIGEN; COMPLEMENT; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; COMPLEMENT MEMBRANE ATTACK COMPLEX; CXCL1 CHEMOKINE; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; NATURAL KILLER CELL RECEPTOR NKG2D; TRANSCRIPTION FACTOR T BET;

ACUTE ANTIBODY MEDIATED REJECTION; ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANTIGEN ANTIBODY REACTION; ARTICLE; CHRONIC ANTIBODY MEDIATED REJECTION; CHRONIC GRAFT REJECTION; COMPLEMENT DEFICIENCY; COMPLEMENT DEPOSITION; COMPLEMENT SYSTEM; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; GRAFT DYSFUNCTION; HEART TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; PANCREAS TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HUMANS; KILLER CELLS, NATURAL;

EID: 84869086847     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.07.330     Document Type: Article

References (85)

1. Gorer P. The detection of antigenic differences in mouse erythrocytes by the employment of immune sera. Br J Exp Pathol 1936, 17:42.
2. Billingham R.E., Brent L. Further attempts to transfer transplantation immunity by means of serum. Br J Exp Pathol 1956, 37:566.
3. Makela O., Mitchison N.A. The role of cell number and source in adoptive immunity. Immunology 1965, 8(6):539.
4. Winn H.J., Baldamus C.A., Jooste S.V., Russell P.S. Acute destruction by humoral antibody of rat skin grafted to mice. J Exp Med 1973, 137(4):893.
5. Gerlag P.G., Koene R.A., Hagemann J.F., Wijdeveld P.G. Hyperacute rejection of skin allografts in the mouse. Sensitivity of ingrowing skin grafts to the action of alloantibody and rabbit complement. Transplant 1975, 20(4):308.
6. Kissmeyer-Nielsen F., Olsen S., Petersen V.P., Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966, 2(7465):662.
7. Jeannet M., Pinn V.W., Flax M.H., Winn H.J., Russell P.S. Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970, 282(3):111.
8. Terasaki P.I., Ozawa M., Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007, 7(2):408.
9. Halloran P.F., Wadgymar A., Ritchie S., Falk J., Solez K., Srinivasa N.S. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplant 1990, 49(1):85.
10. Trpkov K., Campbell P., Pazderka F., Cockfield S., Solez K., Halloran P.F. Pathologic features of acute renal allograft rejection associated with donor-specific antibody, Analysis using the Banff grading schema. Transplant 1996, 61(11):1586.
11. Feucht H.E., Felber E., Gokel M.J., Hillebrand G., Nattermann U., Brockmeyer C., et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991, 86(3):464.
12. Mauiyyedi S., Crespo M., Collins A.B., Schneeberger E.E., Pascual M.A., Saidman S.L., et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002, 13(3):779.
13. Collins A.B., Schneeberger E.E., Pascual M.A., Saidman S.L., Williams W.W., Tolkoff-Rubin N., et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999, 10(10):2208.
14. Takemoto S.K., Zeevi A., Feng S., Colvin R.B., Jordan S., Kobashigawa J., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004, 4(7):1033.
15. Racusen L.C., Colvin R.B., Solez K., Mihatsch M.J., Halloran P.F., Campbell P.M., et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003, 3(6):708.
16. Cohen D., Colvin R.B., Daha M.R., Drachenberg C.B., Haas M., Nickeleit V., et al. Pros and cons for C4d as a biomarker. Kidney Int 2012, 81(7):628.
17. Mauiyyedi S., Pelle P.D., Saidman S., Collins A.B., Pascual M., Tolkoff-Rubin N.E., et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001, 12(3):574.
18. Regele H., Bohmig G.A., Habicht A., Gollowitzer D., Schillinger M., Rockenschaub S., et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002, 13(9):2371.
19. Sis B., Campbell P.M., Mueller T., Hunter C., Cockfield S.M., Cruz J., et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007, 7(7):1743.
20. Solez K., Colvin R.B., Racusen L.C., Sis B., Halloran P.F., Birk P.E., et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007, 7(3):518.
21. Jooste S.V., Colvin R.B., Soper W.D., Winn H.J. The vascular bed as the primary target in the destruction of skin grafts by antiserum. I. Resistance of freshly placed xenografts of skin to antiserum. J Exp Med 1981, 154(5):1319.
22. Jooste S.V., Colvin R.B., Winn H.J. The vascular bed as the primary target in the destruction of skin grafts by antiserum. II. Loss of sensitivity to antiserum in long-term xenografts of skin. J Exp Med 1981, 154(5):1332.
23. Burdick J.F., Russell P.S., Winn H.J. Sensitivity of long-standing xenografts of rat hearts to humoral antibodies. J Immunol 1979, 123(4):1732.
24. Yin D., Zeng H., Ma L., Shen J., Xu H., Byrne G.W., et al. Cutting Edge: NK cells mediate IgG1-dependent hyperacute rejection of xenografts. J Immunol 2004, 172(12):7235.
25. Chen D., Weber M., Lechler R., Dorling A. NK-cell-dependent acute xenograft rejection in the mouse heart-to-rat model. XenoTransplant 2006, 13(5):408.
26. Minami K., Murata K., Lee C.Y., Fox-Talbot K., Wasowska B.A., Pescovitz M.D., et al. C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats. Am J Transplant 2006, 6(5 Pt 1):923.
27. Qian Z., Hu W., Liu J., Sanfilippo F., Hruban R.H., Baldwin W.M. Accelerated graft arteriosclerosis in cardiac transplants: complement activation promotes progression of lesions from medium to large arteries. Transplant 2001, 72(5):900.
28. Qian Z., Lee C.Y., Murata K., Liu J., Fox-Talbot K., Wasowska B.A., et al. Antibody and complement mediated injury in transplants following sensitization by allogeneic blood transfusion. Transplant 2006, 82(7):857.
29. Murata K., Fox-Talbot K., Qian Z., Takahashi K., Stahl G.L., Baldwin W.M. Wasowska BA: Synergistic deposition of C4d by complement-activating and non-activating antibodies in cardiac transplants. Am J Transplant 2007, 7(11):2605.
30. Rahimi S., Qian Z., Layton J., Fox-Talbot K., Baldwin W.M. Wasowska BA: Non-complement- and complement-activating antibodies synergize to cause rejection of cardiac allografts. Am J Transplant 2004, 4(3):326.
31. Wasowska B.A., Qian Z., Cangello D.L., Behrens E., Van Tran K., Layton J., et al. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice. Transplant 2001, 71(6):727.
32. Wang H., Arp J., Liu W., Faas S.J., Jiang J., Gies D.R., et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation. J Immunol 2007, 179(7):4451.
33. Nozaki T., Amano H., Bickerstaff A., Orosz C.G., Novick A.C., Tanabe K., et al. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol 2007, 179(8):5238.
34. Russell P.S., Chase C.M., Winn H.J., Colvin R.B. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994, 152(10):5135.
35. Russell P.S., Chase C.M., Colvin R.B. Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis: lack of progression to sclerotic lesions in B cell-deficient mice. Transplant 1997, 64(11):1531.
36. Uehara S., Chase C.M., Cornell L.D., Madsen J.C., Russell P.S., Colvin R.B. Chronic cardiac transplant arteriopathy in mice. relationship of alloantibody, C4d deposition and neointimal fibrosis. Am J Transplant 2007, 7(1):57.
37. Hirohashi T., Uehara S., Chase C.M., DellaPelle P., Madsen J.C., Russell P.S., et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010, 10(3):510.
38. Hirohashi T., Chase C.M. Della Pelle P, Sebastian D, Alessandrini A, Madsen JC, Russell PS, Colvin RB: A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012, 12(2):313.
39. Arase N., Arase H., Hirano S., Yokosuka T., Sakurai D., Saito T. IgE-mediated activation of NK cells through Fc gamma RIII. J Immunol 2003, 170(6):3054.
40. Arase N., Arase H., Park S.Y., Ohno H., Ra C., Saito T. Association with FcRgamma is essential for activation signal through NKR-P1 (CD161) in natural killer (NK) cells and NK1.1+ T cells. J Exp Med 1997, 186(12):1957.
41. Trotta R., Col J.D., Yu J., Ciarlariello D., Thomas B., Zhang X., et al. Wei M, Mao H, Byrd JC, Perrotti D, Caligiuri MA: TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 2008, 181(6):3784.
42. Roda J.M., Parihar R., Lehman A., Mani A., Tridandapani S., Carson W.E. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006, 177(1):120.
43. Tellides G., Tereb D.A., Kirkiles-Smith N.C., Kim R.W., Wilson J.H., Schechner J.S., et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000, 403(6766):207.
44. Russell P.S., Chase C.M., Winn H.J., Colvin R.B. Coronary atherosclerosis in transplanted mouse hearts. III. Effects of recipient treatment with a monoclonal antibody to interferon-gamma. Transplant 1994, 57(9):1367.
45. Nagano H., Mitchell R.N., Taylor M.K., Hasegawa S., Tilney N.L., Libby P. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997, 100(3):550.
46. Nagano H., Libby P., Taylor M.K., Hasegawa S., Stinn J.L., Becker G., et al. Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: role of interferon-gamma. Am J Pathol 1998, 152(5):1187.
47. Toyoda M., Ge S., Suviolahti E., Pichurin P., Shin B., Pao A., et al. IFNgamma production by NK cells from HLA-sensitized patients after in vitro exposure to allo-antigens. Transpl Immunol 2012, 26(2-3):107.
48. Bergese S., Pelletier R., Vallera D., Widmer M., Orosz C. Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Roles for TNF and IL4. Am J Pathol 1995, 146(4):989.
49. Sawaki J., Tsutsui H., Hayashi N., Yasuda K., Akira S., Tanizawa T., et al. Type 1 cytokine/chemokine production by mouse NK cells following activation of their TLR/MyD88-mediated pathways. Int Immunol. 2007, 19(3):311.
50. Smith J.D., Lawson C., Yacoub M.H., Rose M.L. Activation of NF-kappa B in human endothelial cells induced by monoclonal and allospecific HLA antibodies. Int Immunol. 2000, 12(4):563.
51. Jin Y.P., Singh R.P., Du Z.Y., Rajasekaran A.K., Rozengurt E., Reed E.F. Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Src, paxillin, and focal adhesion kinase in an actin-dependent manner. J Immunol 2002, 168(11):5415.
52. Jaramillo A., Smith C.R., Maruyama T., Zhang L., Patterson G.A., Mohanakumar T. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 2003, 64(5):521.
53. Valenzuela N.M., Reed E.F. The link between major histocompatibility complex antibodies and cell proliferation. Transplant Rev (Orlando) 2011, 25(4):154.
54. Houser S.L., Benjamin L.C., Wain J.C., Madsen J.C., Allan J.S. Constitutive expression of major histocompatibility complex class II antigens in pulmonary epithelium and endothelium varies among different species. Transplant 2004, 77(4):605.
55. Lorber M.I., Wilson J.H., Robert M.E., Schechner J.S., Kirkiles N., Qian H.Y., et al. Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice. Transplant 1999, 67(6):897.
56. Wang Y., Burns W.R., Tang P.C., Yi T., Schechner J.S., Zerwes H.G., et al. Interferon-gamma plays a nonredundant role in mediating T cell-dependent outward vascular remodeling of allogeneic human coronary arteries. FASEB J 2004, 18(3):606.
57. Galvani S., Auge N., Calise D., Thiers J.C., Canivet C., Kamar N., et al. HLA class I antibodies provoke graft arteriosclerosis in human arteries transplanted into SCID/beige mice. Am J Transplant 2009, 9(11):2607.
58. Galvani S., Trayssac M., Auge N., Thiers J.C., Calise D., Krell H.W., et al. A Key Role for Matrix Metalloproteinases and Neutral Sphingomyelinase-2 in Transplant Vasculopathy Triggered by Anti-HLA Antibody. Circulation 2011, 124(24):2725.
59. Akiyoshi T CC, Alessandrini A, Sebastian DP, Della Pelle P, Lee WM, Connolly SE, Farkash E, Yun SH, Russell PS, Colvin RB: Combination of aortic transplant and in vivo microscopy: A new tool for dynamic investigation of Allo-immune reaction. Annual Scientific Exchange. San Antonio, TX, 2011.
60. Aird W.C. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2012, 2(1):a006429.
61. Wieczorek G., Bigaud M., Menninger K., Riesen S., Quesniaux V., Schuurman H.J., et al. Acute and chronic vascular rejection in nonhuman primate kidney transplantation. Am J Transplant 2006, 6(6):1285.
62. Smith R.N., Kawai T., Boskovic S., Nadazdin O., Sachs D.H., Cosimi A.B., et al. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in Cynomolgus monkeys. Am J Transplant 2008, 8(8):1662.
63. Gaston R.S., Cecka J.M., Kasiske B.L., Fieberg A.M., Leduc R., Cosio F.C., et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplant 2010, 90(1):68.
64. Einecke G., Sis B., Reeve J., Mengel M., Campbell P.M., Hidalgo L.G., et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009, 9(11):2520.
65. Hill G.S., Nochy D., Bruneval P. Duong van Huyen JP, Glotz D, Suberbielle C, Zuber J, Anglicheau D, Empana JP, Legendre C, Loupy A: Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011, 22(5):975.
66. Lepin E.J., Zhang Q., Zhang X., Jindra P.T., Hong L.S., Ayele P., et al. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant 2006, 6(7):1560.
67. Colvin R.B. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007, 18(4):1046.
68. Sis B., Jhangri G.S., Bunnag S., Allanach K., Kaplan B., Halloran P.F. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009, 9(10):2312.
69. Sellares J., de Freitas D.G., Mengel M., Reeve J., Einecke G., Sis B., et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012, 12(2):388.
70. Wiebe C., Gibson I.W., Blydt-Hansen T.D., Karpinski M., Ho J., Storsley L.J., et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012, 12(5):1157.
71. Hidalgo L.G., Sis B., Sellares J., Campbell P.M., Mengel M., Einecke G., et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010, 10(8):1812.
72. Sis B., Halloran P.F. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010, 15(1):42.
73. Loupy A., Hill G.S., Suberbielle C., Charron D., Anglicheau D., Zuber J., et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011, 11(1):56.
74. Fildes J.E., Yonan N., Tunstall K., Walker A.H., Griffiths-Davies L., Bishop P., et al. Natural killer cells in peripheral blood and lung tissue are associated with chronic rejection after lung transplantation. J Heart Lung Transplant 2008, 27(2):203.
75. Collins A.B., Chicano S.L., Cornell L.D., Tolkoff-Rubin N., Goes N.B., Saidman S.L., et al. Putative antibody-mediated rejection with C4d deposition in HLA-identical, ABO-compatible renal allografts. Transplant Proc 2006, 38(10):3427.
76. Grafft C.A., Cornell L.D., Gloor J.M., Cosio F.G., Gandhi M.J., Dean P.G., et al. Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrol Dial Transplant 2010, 25(1):307.
77. Zhang Q., Reed E.F. Non-MHC antigenic targets of the humoral immune response in transplantation. Curr Opin Immunol 2010, 22(5):682.
78. West L.J. ABO-incompatible hearts for infant transplantation. Curr Opin Organ Transplant 2011, 16(5):548.
79. Takahashi K., Saito K., Nakagawa Y., Tasaki M., Hara N., Imai N. Mechanism of acute antibody-mediated rejection in ABO-incompatible kidney transplantation: which anti-A/anti-B antibodies are responsible, natural or de novo?. Transplant 2010, 89(5):635.
80. Haas M., Segev D.L., Racusen L.C., Bagnasco S.M., Locke J.E., Warren D.S., et al. C4d deposition without rejection correlates with reduced early scarring in ABO-incompatible renal allografts. J Am Soc Nephrol 2009, 20(1):197.
81. Issa N., Cosio F.G., Gloor J.M., Sethi S., Dean P.G., Moore S.B., et al. Transplant glomerulopathy: risk and prognosis related to anti-human leukocyte antigen class II antibody levels. Transplant 2008, 86(5):681.
82. Benson E.M., Colvin R.B., Russell P.S. Induction of IA antigens in murine renal transplants. J Immunol 1985, 134(1):7.
83. Muczynski K.A., Ekle D.M., Coder D.M., Anderson S.K. Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: characterization, isolation, and regulation of MHC class II expression. J Am Soc Nephrol 2003, 14(5):1336.
84. Stegall M.D., Diwan T., Raghavaiah S., Cornell L.D., Burns J., Dean P.G., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011, 11(11):2405.
85. Farkash E.A., Colvin R.B. Diagnostic challenges in chronic antibody-mediated rejection. Nat Rev Nephrol 2012, 8(5):255.